Ying Ni

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Venues

NPJ precision oncology

Molecular cancer research : MCR

Leukemia & lymphoma

Cancer research

Cleveland Clinic

Case Western Reserve University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Cleveland Clinic Jul 01 2016

United States

Project Staff

Education History

Case Western Reserve University

United States

PHD :: Molecular Medicine

Publications

Hussein Al Sudani, Ying Ni, Philip Jones, Huseyin Karakilic, Lei Cui, Lisa D S Johnson, Peter G Rose, Alexander Olawaiye, Robert P Edwards, Robert A Uger, Gloria H Y Lin, Haider Mahdi
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. NPJ precision oncology 7 (1) (2023)
Yu Sun, Xin Li, Chengqian Yin, Judy Zhang, Ershang Liang, Xianfang Wu, Ying Ni, Joshua Arbesman, Colin R Goding, Shuyang Chen
AMPK phosphorylates ZDHHC13 to increase MC1R activity and suppress melanomagenesis. Cancer research (2023)
Anthony Caputo, Kavya Vipparthi, Peter Bazeley, Erinn Downs-Kelly, Patrick J McIntire, Lauren Ashley Duckworth, Ying Ni, Bo Hu, Ruth A Keri, Mihriban Karaayvaz-Yildirim
Spatial transcriptomics suggests that alterations occur in the preneoplastic breast microenvironment of BRCA1/2 mutation carriers. Molecular cancer research : MCR (2023)
Alan Shen, Michelle Arbesman, Roshan Lodha, Patricia A Rayman, Brandon Bungo, Ying Ni, Timothy A Chan, Brian R Gastman, Jennifer Susan Ko, C Marcela Diaz-Montero, Joshua Arbesman, Pauline Funchain
Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Vipin Shankar Chelakkot, Kiara Thomas, Todd Romigh, Andrew Fong, Lin Li, Shira Ronen, Shuyang Chen, Pauline Funchain, Ying Ni, Joshua Arbesman
MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NFκB pathways accelerates G1/S transition promoting breast cancer progression. NPJ precision oncology 7 (1) (2023)
Marcelo Vailati Negrão, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi Hines, Jacqueline V Aredo, Michael J Dennis, Turja Chakrabarti, Susan C Scott, Paolo Bironzo, Matthias Scheffler, Petros Christopoulos, Albrecht Stenzinger, Jonathan W Riess, So Yeon Kim, Sarah B Goldberg, Mingjia Li, Qi Wang, Yun Qing, Ying Ni, Minh Truong Do, Richard Lee, Biagio Ricciuti, Joao M Victor Alessi, Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A Vaporciyan, George R Blumenschein, Jianjun Zhang, Dwight H Owen, Collin M Blakely, Giannis S Mountzios, Catherine A Shu, Christine M Bestvina, Marina-Chiara Garassino, Kristen A Marrone, Jhanelle E Gray, Sandip Pravin Patel, Amy L Cummings, Heather A Wakelee, Juergen Wolf, Giorgio Vittorio Scagliotti, Federico Cappuzzo, Fabrice Barlesi, Pradnya D Patil, Leylah Drusbosky, Don L Gibbons, Funda Meric-Bernstam, Jiun-Kae Jack Lee, John Victor Heymach, David S Hong, Rebecca S Heist, Mark M Awad, Ferdinandos Skoulidis
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer discovery (2023)
Ying Ni, Ahmed Soliman, Amy Joehlin-Price, Fadi Abdul-Karim, Peter G Rose, Haider Mahdi
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers. Immunotherapy 13 (14) (2021)
Vera Adema, Jack Khouri, Ying Ni, Heesun J Rogers, Cassandra M Kerr, Hassan Awada, Yasunobu Nagata, Teodora Kuzmanovic, Anjali S Advani, Aaron T Gerds, Sudipto Mukherjee, Aziz Nazha, Yogen Saunthararajah, Yazan Madanat, Bhumika J Patel, Francesc Solé, Steffan T Nawrocki, Jennifer S Carew, Mikkael A Sekeres, Jaroslaw P Maciejewski, Valeria Visconte, Hetty E Carraway
Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leukemia & lymphoma 62 (3) (2020)

Ying Ni.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ying Ni